Related Experiment Videos
[Cardiotoxicity of anthracyclines]
Annales De Medecine Interne
|January 1, 1984
Summary
Anthracyclines like doxorubicin can cause acute and chronic cardiotoxicity, increasing heart failure risk with cumulative doses. Early detection via myocardial angioscintigraphy is crucial for prevention.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Context:
- Anthracyclines, such as doxorubicin, are vital chemotherapy agents.
- Their use is limited by significant cardiotoxicity, manifesting acutely or chronically.
- Chronic cardiotoxicity can lead to irreversible heart failure, dose-dependently.
Purpose:
- To review the cardiotoxicity of anthracyclines.
- To discuss risk factors, prevention strategies, and diagnostic methods.
- To highlight areas for future research in managing anthracycline-induced cardiomyopathy.
Summary:
- Cardiotoxicity presents acutely (benign) or chronically (irreversible heart failure), with risk tied to cumulative anthracycline dose.
- Key risk factors include patient age, prior cardiac disease, and mediastinal radiotherapy.
- Prevention involves adhering to dose limits and early detection using sensitive methods like myocardial angioscintigraphy.
Impact:
- Establishes myocardial angioscintigraphy as a preferred diagnostic tool over biopsy or echocardiography.
- Identifies critical research needs, including understanding mechanisms, clinical trials for continuous infusions, and developing less cardiotoxic agents.
- Aims to improve patient outcomes by mitigating severe cardiac events during chemotherapy.